NSTM Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.01 and $0.04. With a market capitalization of about $493.32 thousand, NovelStem International Corp. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.49). Key stats such as the average daily volume over the past year has been around 8.99 thousand shares, volume is running light vs its 52-week average. Headquartered in Boca Raton, FL, NovelStem International Corp. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Jan H. Loeb, the company employs approximately 2 people and listed since November 12, 1993. NovelStem International Corp. concentrates its efforts on pioneering and introducing diagnostic solutions for cancer treatment, specifically with the goal of mitigating chemotherapy resistance.

Average 10-day trading volume of 3.76 thousand shares is below the 3-month average of 60.95 thousand, indicating normal recent market interest.

NovelStem International Corp. has 49.33 million shares outstanding. The public float is 20.44 million shares, elevated short interest at 0.03% of float. This equals 5.34 thousand shares. The short ratio is 0.12 days. Institutional investors hold 0.12% of the float. Insiders own 58.57%.

Valuation shows NovelStem International Corp. trading at a premium to the broader market with a P/E of -1.54.

Our AI price prediction model suggests that NovelStem International Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

NovelStem International Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

NovelStem International Corp. trades at a P/E ratio of -1.54, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.24 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.19, also above market averages.